CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Asthma controller therapies (incl. prednisone/prednisolone)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug232 Asthma reliever therapies Wiki 1.00
drug796 Dupilumab (SAR231893/REGN668) Wiki 1.00
drug519 Cannabidiol Wiki 1.00
drug1738 PLACEBO Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D001249 Asthma NIH 0.50

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002099 Asthma HPO 0.50

There is one clinical trial.

Clinical Trials

1 One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. Secondary Objectives: - To evaluate the long-term efficacy of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. - To evaluate dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study with regard to: - Systemic exposure. - Anti-drug antibodies (ADAs). - Biomarkers.

NCT03560466 Asthma Drug: Dupilumab (SAR231893/REGN668) Drug: Asthma controller therapies (incl. prednisone/prednisolone) Drug: Asthma reliever therapies
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: The number (n) and percentage (%) of patients experiencing any TEAE

Measure: Treatment-emergent adverse events (TEAEs)

Time: From Day 1 up to Week 64

Secondary Outcomes

Description: Annualized rate of severe asthma exacerbation events, during the treatment period

Measure: Severe asthma exacerbation events

Time: From Day 1 up to Week 52

Description: Change in percentage (%) predicted forced expiratory volume in 1 second (FEV1) - Clinically significant changes from baseline

Measure: Change in % predicted FEV1

Time: From Day 1 up to Week 64

Description: Change in absolute FEV1 - Clinically significant changes from baseline

Measure: Change in absolute FEV1

Time: From Day 1 up to Week 64

Description: Change in forced vital capacity (FVC)

Measure: Change in FVC

Time: From Day 1 up to Week 64

Description: Change in forced expiratory flow (FEF) 25-75%

Measure: Change in FEF

Time: From Day 1 up to Week 64

Description: Serum dupilumab concentrations - Changes from first dupilumab injection

Measure: Assessment of dupilumab concentration

Time: From Day 1 up to Week 64

Description: Titers of Anti-dupilumab antibodies

Measure: Assessment of immunogenicity

Time: From Day 1 up to Week 64

Description: Blood: Eosinophil count

Measure: Assessment of blood Eosinophil count

Time: From Day 1 up to Week 64

Description: Serum: total IgE

Measure: Assessment of total immunoglobulin E (IgE)

Time: From Day 1 up to Week 64

Related HPO nodes (Using clinical trials)

HP:0002099: Asthma
Genes 152
RSPH1 DOCK8 NKX2-1 CBL TNF SPAG1 FOXJ1 MCIDAS LIG4 AFF4 GAS2L2 LMX1B SCN4A DNAH1 TET2 CCDC151 ARL6 DNAL1 SCGB3A2 ALMS1 FOXH1 CCL11 CCDC28B ADRB2 COMT CDON SHH CFAP221 SDHD PEX5 GRHL2 DNAAF1 GP1BA RPGR RSPH9 STK36 JMJD1C PTGER2 DNAH9 TBCK COX4I2 OFD1 LRBA RSPH4A DNAH5 HIRA IL4R RREB1 STXBP1 NME8 GAS8 COL5A1 TTC12 NEK9 NSUN2 CFTR MUC7 IDS PGM3 GLI2 CCDC65 DOCK8 CFAP298 RUNX1 GTF2H5 TBX1 PLCG2 NOD2 CFAP300 TBX21 PLA2G7 ALOX5 ZIC2 DNAI1 PTCH1 MTOR DNAJB13 TRAIP SPEF2 SRSF2 CCDC40 ALMS1 ZMYND10 BBS1 COL1A1 SIX3 GAS1 SIK3 IL13 NODAL CCDC39 ARMC4 TALDO1 GP1BB TTC25 DNAAF2 ELOVL4 DNAI2 ARVCF DDX41 NKX2-1 TBX1 NFKB2 DRC1 FCGR2A DISP1 NEK10 USP7 TGIF1 SPINK5 RSPH3 LRRC6 CARMIL2 HLA-G LIFR DNAAF5 CCNO CDSN COL5A2 TGFB1 GP9 FLG PLA2G7 HYDIN DNAAF6 SEC24C CASP8 SUFU CCDC114 CCDC103 ASXL1 LRRC56 PEPD SPINK5 FGF8 DNAAF4 HNMT BCL11B CCDC151 ERCC2 DLL1 MS4A2 GP1BB DNAAF3 CARD11 UFD1 RIC1 ADA TDGF1 PGM3 FGFR1 DNAH11
Protein Mutations 4
D299G G16R Q27E T399I
SNP 18
rs1042711 rs1042713 rs1042714 rs1042718 rs11958940 rs11959427 rs12654778 rs12936231 rs1504982 rs17778257 rs1800888 rs1801275 rs1805010 rs2053044 rs2895795 rs324011 rs324015 rs4950928